Fig. 1
From: A cascade targeting strategy based on modified bacterial vesicles for enhancing cancer immunotherapy
Synthesis and characterization of siRNA@PLOV. a Flow cytometry analysis of Cyp versus Dio intensity in the mixture or fused of OMVs and PTSLs. b CLSM images of PTSL (Cyp), OMV (Dio) and PLOV. c A pair of Förster resonance energy transfer (FRET) fluorescence dye DiO and DiI is chosen to conduct the fusion process of OMVs with the increasing amounts of PTSLs. d Hydrodynamic size and TEM images of the resulting PLOV. e SDS-PAGE and western blot protein analysis of FijB and SipC from OMVs and PLOV. f Schematic illustration of the transwell system experiment. The 4T1 cells are cultured in the upper chamber and BMDCs are cultured in the lower chamber. After 4T1 cells with treatments of laser, BMDCs are collected for analysis or transported to another transwell system with T cells in upper chamber. g The percentage of DCs derived of the flow cytometry analysis of CD80 and CD86. h CFSE-labeled T cells (105) are incubated with BMDCs which has been treated with formulations (103 particles/mL), and the proliferation of T cells is analyzed by flow cytometry